Table 4. Multivariate analysis of prognostic factors for PFS and OS.
| Parameters | Group | PFS | OS | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| CA-125 | <200 | 1 | 1 | ||||
| ≥200 | 2.787 | 1.34–5.86 | 0.006* | 3.787 | 1.37–10.47 | 0.010* | |
| Stage | I, II | 1 | 1 | ||||
| III, IV | 4.981 | 2.05–12.12 | 0.001* | 4.329 | 1.33–14.12 | 0.015* | |
| Histology | Non-serous | 1 | 1 | ||||
| Serous | 1.446 | 0.53–3.98 | 0.475 | 3.182 | 0.67–15.16 | 0.146 | |
| HER3-FISH | Negative | 1 | - | ||||
| Positive | 2.977 | 1.18–7.49 | 0.021* | - | - | - | |
| Akt | Negative | 1 | - | ||||
| Positive | 1.233 | 0.65–2.34 | 0.522 | - | - | - | |
| S6 | Negative | 1 | 1 | ||||
| Positive | 1.217 | 0.62–2.40 | 0.571 | 1.106 | 0.50–2.45 | 0.804 | |
CA-125, cancer antigen-125; CI, confidence interval; FISH, fluorescence in situ hybridization; HER, human epidermal growth factor receptor; HR, hazard ratio; PFS, progression-free survival.
*p-value <0.05.